Kazia Therapeutics (KZIA) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Kazia Therapeutics has unveiled encouraging Phase I study results at the ASTRO 2024, showing that its drug, paxalisib, when used with radiation therapy, may offer a new treatment avenue for patients with brain tumors linked to PI3K pathway mutations. The study demonstrated a 67% partial response rate, which is notably higher than historical rates for standard whole brain radiation therapy. With plans for a potential pivotal registration study, Kazia Therapeutics is advancing its commitment to addressing the challenges of brain cancer treatment.
For further insights into KZIA stock, check out TipRanks’ Stock Analysis page.
